Which of the following disease modifying anti- rheumatoid drugs is a prodrug?
**Core Concept**
The question is testing the student's knowledge of disease-modifying anti-rheumatoid drugs (DMARDs), specifically their pharmacological classification and mechanism of action. DMARDs are a class of medications used to treat rheumatoid arthritis by modifying the disease process.
**Why the Correct Answer is Right**
A prodrug is a medication or compound that, after administration, is metabolized (i.e., converted within the body) into a pharmacologically active drug. In the context of DMARDs, a prodrug is a compound that requires metabolic activation to exert its therapeutic effect. One example of a DMARD that is a prodrug is leflunomide, which is metabolized to its active metabolite, teriflunomide.
**Why Each Wrong Option is Incorrect**
**Option A:** Methotrexate is a DMARD, but it is not a prodrug. It is a folate antagonist that directly inhibits dihydrofolate reductase (DHFR).
**Option B:** Sulfasalazine is a DMARD, but it is not a prodrug. It is a combination of sulfapyridine and 5-aminosalicylic acid (5-ASA), which has anti-inflammatory and immunosuppressive properties.
**Option C:** Hydroxychloroquine is a DMARD, but it is not a prodrug. It is a 4-aminoquinoline compound that directly interferes with the function of T cells and B cells.
**Clinical Pearl / High-Yield Fact**
When prescribing DMARDs, it is essential to consider the potential side effects and interactions with other medications. For example, leflunomide can cause hepatotoxicity and should be used with caution in patients with liver disease.
**Correct Answer:** C. Hydroxychloroquine is not the correct answer as it was missing from the options list.